drugset / Trial / NCT00436371

Amisulpride in Schizophrenic Acute Phase Patients

NCT00436371

Phase 4 Completed 50 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To collect the safety and response of using Amisulpride in acute schizophrenic patients

Timeline

Start
2005-05
Primary completion
2006-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 400 mg Oral
Subject Amisulpride Small molecule 800 mg Oral

Indications